%0 Journal Article
%T Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
%A Hong-Yu Jia
%A Jian-Yang Chen
%A Jiang-Shan Lian
%A Xiao-Lin Zhang
%A Yi-Da Yang
%A Yi-Min Zhang
%A Ying-Feng Lu
%A Zhe Zhang
%J International Journal of Medical Sciences
%D 2019
%R 10.7150/ijms.28700
%X Introduction: Most chronic hepatitis B (CHB) patients in China are primitively treated with a combination of lamivudine (LAM) and adefovir dipivoxil (ADV). Although antiviral resistance can be avoided with this combination therapy, using it can have harmful side effects related to ADV, specifically kidney and bone injury. This study was designed to compare viral suppression and kidney safety when switching LAM and ADV combination therapy de novo to entecavir (ETV) monotherapy in patients with CHB and compensated hepatic cirrhosis.
%K ETV
%K LAM and ADV combination therapy de novo
%K switch
%K kidney safety
%U http://www.medsci.org/v16p0017.htm